PPD

ICON Founder to Retire as Board Chairman

Friday, December 18, 2009 07:23 AM

John Climax will retire as board chairman of Dublin-based contract research organization (CRO) ICON, effective December 31. Climax founded the company 19 years ago. He will remain as a board member, while Bruce Given steps into the role of chairman. Given, a healthcare products consultant, has served on ICON’s board for five years. Prior to becoming a consultant, he was president and CEO of Encysive Pharmaceuticals.

More... »

PPD Paying Cash for Acquisitions, Shelling Out $77M for BioDuro

Monday, December 7, 2009 07:48 AM

Wilmington, N.C.-based PPD, a global contract research organization (CRO), is spending its cash hoard in a buying spree to “dominate” the Asia-Pacific region. The CRO doled out $77 million for its latest acquisition of BioDuro, a drug discovery outsourcing company focused on integrated drug discovery programs and services. The deal was completed last week just a couple weeks after it paid cash for another CRO in China. 

More... »

PPD in Compound Partnering Deal with Janssen Pharmaceutica

Tuesday, November 24, 2009 07:38 AM

PPD, a global CRO, has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other to treat complicated skin, skin structure and respiratory infections.

More... »

PPD Continues China Expansion with Deal to Acquire Drug Discovery Company BioDuro

Thursday, November 19, 2009 03:35 PM

Less than a month after announcing its acquisition of China-based contract research organization (CRO) Excel PharmaStudies and plans to dominate the Asia-Pacific region,PPD, the Wilmington, N.C.-based global CRO has signed an agreement to acquire BioDuro LLC, a drug discovery outsourcing company. The acquisition of the 660-employee company will expand PPD's drug development capabilities in China.  

More... »

PPD to Buy China-Based Excel PharmaStudies, Spin Off Compound Partnering

Monday, November 2, 2009 06:09 AM

Signaling a major strategic shift, PPD is focusing on Asia-Pacific—China in particular. The company has made a big move in the region by entering into an agreement to acquire Excel PharmaStudies, one of the largest contract research organizations (CROs) in China, which will provide PPD additional capacity in China’s rapidly growing pharmaceutical market. PPD also plans to spin off its compound partnering business from its core CRO work and invest $100 million in Celtic Therapeutics.

More... »

PPD to Buy China’s Excel PharmaStudies

Wednesday, October 28, 2009 09:06 AM

PPD has entered into an agreement to acquire Excel PharmaStudies, one of the largest contract research organizations (CROs) in China, providing PPD additional capacity and expertise in the rapidly growing clinical research market.

More... »

PPD Opens Central Lab in Singapore

Tuesday, September 29, 2009 08:40 AM

PPD recently opened a new central lab facility in Singapore, where the CRO has had an office for more than 10 years. 

More... »

LabConnect Hires Former Quintiles Exec to be COO

Friday, August 28, 2009 07:32 AM

LabConnect, a provider of central laboratory services to the clinical trial industry, appointed former Quintiles executive Frank Morrow, Ph.D., as its chief operating officer.

More... »

PPD’s Revenues Fall, Earnings Boosted by Piedmont Sale

Wednesday, July 22, 2009 07:00 AM

Wilmington, N.C.-based PPD's second quarter revenues fell nearly $50 million to $355.2 million, but its earnings per share were boosted by the sale of its subsidiary, Piedmont Research Center, which was part of the company's discovery sciences segment.

More... »

PPD to Cut 270 Employees in North America

Tuesday, July 14, 2009 07:00 AM

Wilmington, N.C.-based contract research organization (CRO) PPD is laying off a total of 270 employees in North America, including 80 employees from its North Carolina headquarters.

More... »